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Lost in translation: barriers to implementing clinical 
immunotherapeutics for autoimmunity
 
Matthias G. von Herrath and Gerald T. Nepom
 
Induction of selective, autoantigen-specific tolerance is the “holy grail” for 
the treatment and prevention of autoimmune diseases. Despite successes in 
many differential murine models, rational and efficient translation to the 
clinic has been difficult. During the 5th Annual Federation of Clinical 
Immunological Societies (FOCIS) Meeting, May 12–16, 2005, in Boston, MA, 
a Kirin-sponsored “Ideashop” was convened to discuss this theme amongst 
scientists, clinicians, industry partners, and funding agencies.
 
The major barriers delaying the trans-
lation of basic research that were artic-
ulated in the workshop were not the
remaining gaps in scientific knowledge,
but rather cultural and communication
gaps in a field that has long been ori-
ented toward fundamental discovery
research, and in which the new era of
“interventional immunology” is in its
infancy. Here, we discuss the various
problems facing the field, including the
difficulty in translating animal models
to human intervention trials, and delin-
eate a possible roadmap for success.
 
Exciting observations; then what?
 
A translational roadmap for a vast ma-
jority of the discovery-oriented immu-
nology research community is cur-
rently uncharted and thus nearly
impossible to follow. Researchers in
academia are woefully unprepared and
untrained for the complex, arduous,
and difficult process of translating basic
immunology to the clinic, as trainees
are taught to focus on scientific discov-
ery. The academic immunology re-
search community has been successful
in creating the infrastructure to nurture
and reward discovery research. How-
ever, upon making a discovery with
therapeutic potential, it is rare for an
academic investigator to think about or
have access to the resources necessary
to nurture translational opportunities.
Most senior immunologists can cite ex-
amples of lost opportunities in which
potential clinical advances were de-
railed by a failure to pursue early
partnerships with industry and legal
experts, or by unskilled negotiations
that created unnecessarily complicated
agreements or royalty arrangements
and hindered progress. Yet knowledge
of the legal parameters involved in
these collaborative ventures is only one
piece of the puzzle. It is perhaps more
important to develop a culture in
which translational goals are a priority,
so that the motivation to seek out clin-
ical colleagues, to reach fair compro-
mises between academic, industrial,
and regulatory entities, and to establish
a collegial relationship with institu-
tional intellectual property officers is a
reasonable expectation, rather than a
rare exception.
 
Is “academic R
 
&
 
D” an oxymoron?
 
Academic institutes are not well-suited
for the collaborative therapeutic devel-
opment that is needed for translational
research in autoimmunity. The key is-
sues are well-illustrated by attempts to
induce antigen-specific tolerance in pa-
tients with type 1 diabetes. The major
work in this area is underwritten by the
National Institutes of Health (NIH) and
nongovernment organizations such as
the Juvenile Diabetes Research Founda-
tion (JDRF), with a relative absence of
industry support. As a consequence, the
approaches are largely investigator initi-
ated and are sometimes uncoordinated,
with no overarching prioritization.
Grants of short duration (typically 3
years) that are reviewed by discovery-
oriented basic investigators are simply
not adequate, as it may take 5 years or
more to apply ideas from mouse models
to testing in humans. Yet short-term
grants remain the principal mechanism
for funding investigator-initiated transla-
tional work. Several important attempts
are underway to address this fundamental
problem, including a new prioritization
review system within the TrialNet con-
sortium (http://www.niddk.nih.gov/
fund/diabetesspecialfunds) sponsored by
the National Institute of Diabetes and
Digestive and Kidney Diseases, a strate-
gic planning process within the Im-
mune Tolerance Network, and a refo-
cusing of the funding portfolio of the
JDRF toward applied research goals.
Nevertheless, allocating scarce research
funds for infrastructure at the expense
of basic research continues to be un-
palatable for a field in which indus-
try partners—the traditional source for
clinical trials and product develop-
ment—have not materialized.
It is also fair to ask whether academ-
ically directed clinical research is the
best approach. Some therapeutic ave-
nues, such as cell-based therapies, are
inherently expensive and would benefit
from industrial partnerships that could
help cover early development costs. In-
dustry is also generally more efficient in
dealing with the regulatory issues that
surround clinical trials. In the case of
diabetes immunotherapy, complicated
quality of life issues also arise, as the
short-term benefits of replacing insulin
therapy are currently used as a clinical
endpoint, whereas the real medical
benefit lies in the prospect of decreas-
ing long-term diabetic complications.
These and other complex issues necessi-
tate close interactions with the Food
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and Drug Association (FDA) and other
regulators during trial development—
interactions not known to be a strong
suit for most academic investigators. A
specific issue for immune-based inter-
ventions and tolerance induction in au-
toimmunity is the need to develop sur-
rogate markers for therapeutic efficacy
(which again requires FDA involve-
ment) in order to optimize assays to
measure alterations of autoimmune re-
sponses in blood samples and to define
the clinical indicators of successful or
deleterious outcomes. How many aca-
demic immunologists think about (or
are even aware of) these issues? It will
therefore be important to allocate funds
to create infrastructure within aca-
demic institutes to facilitate interactions
with regulatory bodies.
 
Are animal models letting us down?
 
The historical hand-off juncture be-
tween basic and clinical immunology
has been the demonstration of thera-
peutic efficacy in animal models of au-
toimmunity. But in many animal mod-
els, translating these findings to humans
may be a huge leap for clinicians. One
problem is that cells traveling within the
human blood, which is our main source
of readily accessible autoantigen-specific
immune cells, might not accurately re-
flect the events taking place in a given
autoimmune target organ, such as the
brain or pancreatic islets of Langerhans.
This simple observation pinpoints an
important problem with our scientific
approach. When studying animal mod-
els, we generally recover cells from or-
gans and tissues that we think will pro-
vide the most reliable answer to the
question asked. In the case of diabetes,
these include the pancreatic draining
lymph node, the islet cells themselves
and sometimes the spleen—all sites that
are not readily accessible in humans. Al-
though this strategy gives us good an-
swers in animal models, it misses a cru-
cial step in translating the discovered
mechanistic insight to clinical trials:
how to test for the establishment of the
same protective mechanism, such as the
development of antigen-specific toler-
ance, in humans. For example, the de-
letion of aggressive T cells or induction
of regulatory T (T reg) cells—com-
monly used approaches for ameliorating
autoimmunity in mice—is reflected in
the lymph nodes or spleen but not in
the peripheral blood of rodents, sug-
gesting that monitoring peripheral cir-
culating cell populations in humans
might not be fruitful. 
Another difficulty that arises in the
design and monitoring of clinical trials
is determining the correct antigen dose
for therapies, which cannot necessarily
be “scaled up” directly from mouse to
human. In a recent diabetes prevention
trial (1), oral insulin was given to predi-
abetic patients based on overwhelming
evidence from animal models that oral
insulin can induce T reg cells that sup-
press aggressive antiislet responses in
the pancreatic lymph node and thus
prevent disease. It was clear that, in
mice, this autoantigen-induced sup-
pressive effect was dose dependent, as
very low or very high oral insulin dos-
ages did not have the desired effect
(2,3). When designing the human trial,
the investigators were faced with the
difficult question of how to translate a
rather large insulin dose (1 mg p.o.
2
 
 
 
/week) in the mouse for human
application. They chose to emphasize
safety rather than simply scale up from
the animal model—a cautious and logi-
cal choice—and used a comparatively
low dose (7.5 mg), based on gut size
and body weight. Interestingly, a par-
tial response reflected by delayed dis-
ease progression was noted only in a
subgroup of patients who already had
significant signs of antiislet autoim-
munity (as assessed by autoantibodies).
Since we have no reliable way to cor-
relate a given stage in the development
of autoimmunity in animal models to
the course of human diabetes, there is
really no straightforward way to apply
the enormous body of animal data to
the rational determination of antigen
dose in future human trials. 
Another example of the difficulty
in translating antigen-specific ap-
proaches from mice to humans is the
failed clinical trials using altered peptide
ligands of myelin basic protein (MBP)
in patients with multiple sclerosis. The
peptides chosen for the human thera-
peutics were based on inbred mouse
models of experimental autoimmune
encephalomyelitis, in which disease is
induced by MBP peptide administra-
tion. The human trial was quickly ter-
minated when it became evident that
some patients were responding to the
peptide as an agonist, with deleterious
clinical consequences (4,5). In retro-
spect, this adverse response might have
been predicted if human in vitro stud-
ies using polyclonal cell populations or
mouse studies using genetically diverse
animal models had been performed,
rather than relying on a single animal
model. Indeed, the genetic diversity
among human subjects may necessitate
individual predictive testing of peptide
responsiveness, analogous to provoca-
tive allergen testing before desensitiza-
tion therapy, as a necessary component
of future trials. In this manner, it may
be possible to distinguish which pa-
tients are likely to have a deleterious
response to the peptide therapeutic
(such as an agonist response or aug-
mentation of autoaggressive type 1
helper or cytotoxic T cell responses),
and which patients are likely to benefit
from such treatment.
 
Inbred animals: multiple copies of one 
individual
 
Human genetic diversity is another
monster in the immunological closet,
which is becoming hard to ignore. The
more we know about the impact of ge-
netic diversity on immune function,
the more variable phenotypes we begin
to recognize, even among subjects with
the same clinical diagnosis. Yet most
animal models of autoimmunity use a
very small number of highly inbred
mouse strains. Type 1 diabetes research
is a flagrant example of this, as it is
heavily reliant on the nonobese dia-
betic (NOD) mouse model, despite the
fact that the NOD strain has a number
of unique immunological defects (6)
that are not found in other mouse
strains and likely not in most human
patients with diabetes, either. Clinical
immunologists would be reluctant to
draw major conclusions based on the
study of a single individual, but basic
immunologists do this routinely by
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testing what are essentially multiple
copies of a single animal.
How can we increase the confi-
dence of translating from mouse to
man? It is impossible to argue with the
major insights into antigen-specific tol-
erance that have been gained from test-
ing in well-defined inbred mouse mod-
els of autoimmunity. However, we
may need to acknowledge a new set of
criteria for translation, in which valida-
tion of a finding made in genetically di-
verse models is a required component
(7). Genetically diverse models will not
only be critical for assessing disease
manifestations themselves, but will be
even more important for evaluating the
response to a particular therapy. An
alternative approach that offers some
possibilities for modeling human ge-
netic diversity is the utilization of par-
tially humanized mice (8,9,10). Even in
these models, however, there are limi-
tations to the diversity that can be
modeled. For example, autoimmune
disease models in human HLA-trans-
genic mice show major differences in
antigen epitope recognition by T cells
and in disease penetrance, depending
on whether they express a single HLA
molecule or two different HLA mole-
cules. Since every human expresses be-
tween 8 and 12 HLA molecules, it is
doubtful whether it will be possible to
create an animal model that faithfully
represents this important immunologic
control element. Human TCR trans-
genic mice are useful for recapitulating
a particular human T cell response.
However, these mice can still be seen
as multiple copies of a single genetic
individual, and findings in these mice
are not likely to be translate into useful
immunotherapies for the human popu-
lation in general. Indeed, is it too un-
comfortable to ask whether, in some
cases, in vitro human studies are more
likely to be informative than in vivo
mouse work? If no mouse model is
perfect, at what point is it no longer
cost effective to utilize scarce resources
to create additional mouse models?
Rather, important and promising ob-
servations made in mouse models could
be solidified by proof-of-principle in
vitro studies using human blood cells.
This strategy might also have an added
benefit if the goal is the induction of
antigen-specific regulation or toler-
ance. As we are still in the process of
establishing reliable in vitro assays that
accurately reflect the induction of anti-
gen-specific tolerance in vivo, such in-
vestigations might be a useful step in
reaching this goal.
 
Opportunity for substantial change?
 
Some of the structural barriers to trans-
lational research are deeply entrenched
in the academic system, and are beyond
the scope of this discussion, which is
centered on immunologic tolerance.
Tenure, promotion, and funding deci-
sions that constrain the training and
performance of translational and clini-
cal immunologists are certainly issues
needing redress. However, with respect
to the opportunities that now exist in
the immunological community, we are
blessed with a large array of potential
immunotherapeutic strategies that are
in need of testing and translation (11).
Substantial changes need to be made if
we are to avoid a piecemeal approach
in the near term, and failed or lost ther-
apeutic opportunities in the future.
Some initiatives are now underway,
such as the FOCIS Centers of Excel-
lence program, which provides a struc-
ture in which translational and clinical
immunologists at collaborating institu-
tions can self-organize in order to gar-
ner local resources more effectively.
Consortia such as the immune toler-
ance network and Trialnet have a key
role to play on the national level,
where firm NIH support is essential.
Constructing a useful translational
roadmap for academic researchers to
follow, like that proposed in Fig. 1,
will require a substantial effort that is
compelled by the prospect of therapeu-
tic interventions in a vast array of hu-
man diseases. Immediately after a new
discovery has been made, it will be es-
sential for the academic institute to
support a rapid evaluation of its thera-
peutic potential and the securing of in-
tellectual property. Even at this early
stage, designated skilled officials should
Figure 1. A translational roadmap for academic researchers.
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contact potential industry partners and
establish relationships that will be cru-
cial for translating the invention to the
clinic. Indeed, academics and industry
have diverging goals for follow-up ex-
perimentation (mechanistic insights and
publications versus toxicology, safety,
and reproducibility), and financing will
be needed to satisfy both groups. We
also believe that the individual investi-
gator should remain involved through-
out the discovery and development
process and that industry partners must
accept the possibility that the new in-
tervention may have undesirable as
well as desirable effects.
The potential impact of immuno-
logic therapies on human health is
enormous, and the opportunity to ad-
vance our knowledge of immunology
in concert with clinical experience is
equally large. For this vision of inter-
ventional immunology to realize its full
potential, however, a smoother path
for academic scientists aspiring to trans-
lational goals is needed. All parts of this
enterprise—funding agencies, regula-
tors, investigators, industry, and aca-
demic institutions—need to recognize
that the cost of lost opportunity is high.
 
The authors are grateful for the generous support for 
the Kirin Ideashop series by Kirin Pharmaceuticals. In 
addition, we especially thank Eli Sercarz, who initiated 
this forum several years ago.
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